ASEAN Post-Marketing Alert System (PMAS) Regional Linkage for Myanmar

1. Key takeaways

Myanmar participates in the ASEAN Post-Marketing Alert System (PMAS). This system is the mechanism through which member states share vigilance information within the region, and the Myanmar FDA carries out market supervision and issues notifications on the basis of PMAS reports. Information on unregistered or non-conforming products discovered in other ASEAN countries is transmitted through PMAS into Myanmar’s market supervision practice.

GRZAN note: the practical effect of this mechanism is that a safety notification in any ASEAN market can become the trigger for action in Myanmar. Companies managing regional compliance must not treat Myanmar as a single market isolated from the others. The linkage can be recorded as: 1 regional vigilance system (PMAS), 2 categories of information sources, and 1 set of local supervision practices. In other words, the information that shapes Myanmar enforcement does not all originate in Myanmar, and the practices that follow it are implemented locally, so regional awareness and local readiness must be designed to work together.

2. Legal basis

The table below summarises the system, Myanmar’s practice under it, the enforcement basis and the sources on which the observations rest.

3. Expert insights

Insight 1: PMAS connects Myanmar into the regional vigilance network. Secure information sharing allows Myanmar to make use of testing and investigation conclusions already completed by other member states. For the authority this multiplies its reach without multiplying its own laboratory workload; for companies it means that the quality of information arriving in Yangon is now the quality of information generated anywhere in ASEAN, and it arrives without the company having any local notice of the underlying event. The only reliable defence is knowing about the problem at the same speed the authority does.

Insight 2: regional notifications serve as an evidence source for Myanmar enforcement actions. The Myanmar FDA expressly cited PMAS reports in its notifications, showing that its enforcement is supported by external information. This matters for planning because it removes the assumption that enforcement requires a locally detected problem: the evidentiary foundation can arrive from abroad, fully documented, and the local action can follow quickly.

Insight 3: the notification examples show enforcement covering multiple batches and product categories. The two notifications, covering 29 and 30 items respectively, show that the mechanism operates on a routine basis rather than as a one-off exercise. Regularity is precisely what makes the mechanism consequential for planning: a system that fires occasionally can be ridden out, but a system that runs continuously must be met with continuous monitoring on the company side. It also shows that the notifications extend beyond medical devices into cosmetics, which underlines that the sharing mechanism covers consumer health products broadly rather than a single narrow category.

Insight 4: enforcement against unregistered products is not blocked by the absence of a dedicated law. The authority handles such cases by invoking the general provisions of the Public Health Law. Companies should therefore not read the legislative gap as an enforcement vacuum; the general clauses give the authority a usable instrument, and the notification examples show that the instrument is in active use.

Insight 5: companies must manage safety information on a regional basis. A product problem in any single market can be transmitted into Myanmar, so managing each market in isolation carries real risk. The correct design is a single internal process that evaluates an event once and applies the conclusion across all ASEAN markets where the product is present, with Myanmar explicitly included in the scope of that process. Isolated management fails quietly: each local team assumes the issue belongs to another market, and no one checks the one market where the notification actually lands.

4. Practical recommendations

• Include Myanmar in the scope of regional vigilance information monitoring. Watch notifications concerning the same product categories in other ASEAN markets, and treat them as early warnings for Myanmar exposure rather than as someone else’s enforcement news.
• Establish a unified internal assessment process for safety events. When a problem is found in one market, start a cross-market assessment immediately, so the same defect does not have to be discovered market by market.
• Retain product batch and distribution records for traceability. They are the raw material for responding to possible notifications and investigations, and they take far longer to reconstruct than to keep. Traceability is also what allows the company to scope a problem precisely instead of over-recalling by default.
• Cooperate proactively through the local authorised representative once a notification occurs. Prompt engagement reduces the knock-on effects on other aspects of the company’s compliance standing.
• Do not treat the absence of a dedicated law as an enforcement vacuum. Prepare documentation to the strictest applicable standard, because general provisions are demonstrably sufficient for enforcement action.

5. Verification checklist

• □ Myanmar’s participation in the ASEAN PMAS mechanism has been confirmed
• □ Myanmar has been included in the scope of regional vigilance information monitoring
• □ A unified cross-market assessment process for safety events has been established
• □ Product batch and distribution traceability records have been established
• □ The responsible person for responding to notifications has been designated
• □ Documentation has been prepared to the strictest applicable standard
• □ The items have been incorporated into the registration ledger

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Myanmar. Our team prepares the technical dossier to ASEAN CSDT structure, manages submission and deficiency responses with the Myanmar FDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com